| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-10 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0004
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-502
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5058
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-27 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-27
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-74 |
| filingDate |
2005-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa22f97027bdf5075d7db0db8a3ed6fb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0268f39807177b68c3563d23c3643d69 |
| publicationDate |
2005-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2005201938-A1 |
| titleOfInvention |
Method for selectively inhibiting ghrelin action |
| abstract |
The present invention provides a method selectively inhibiting ghrelin activity to treat a variety of diseases including obesity and related disorders, particularly in individuals who are genetically predisposed. One aspect of the invention comprises administering an agent that effectively neutralizes ghrelin. Another aspect comprises administering a ghrelin receptor (growth hor- mone secretagogue receptor) antagonist. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004121407-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10317418-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9821042-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10039813-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9724396-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010261291-A1 |
| priorityDate |
2000-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |